The settlement involves Cardinal Health, McKesson, AmerisourceBergen, Johnson & Johnson and Teva. Attorneys general from North Carolina, Tennessee, Pennsylvania and Texas agreed to the settlement, which includes $22 billion in cash and $26 billion worth of generic opioid addiction treatment, product distribution and data tracking measures.
Each state and its local governments would get a share of the $22 billion to provide addiction treatment, paramedic services and telehealth treatment, according to The Hill.
McKesson would pay the most out of all the companies, at $6.68 billion over 18 years. Cardinal Health and AmerisourceBergen would each pay about $5.6 billion over 18 years and J&J would pay $4 billion over two to three years. Teva would pay $250 million over 10 years and supply $23 billion of its generic suboxone drug over 10 years.
The framework settlement is an agreement in principle and has not yet been finalized.
Read the full article here.
More articles on opioids:
Drug companies reach last-minute opioid settlement
West Virginia receives $6.5M for state opioid abuse program, telehealth services
HHS creates clinician resource for tapering patients’ opioid use
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
